Latest Us Market News

Rio Tinto reports a robust 13% year-on-year increase in copper equivalent production for Q2 2025, alongside record bauxite output and progress on key projects like Simandou and Oyu Tolgoi. The company maintains its 2025 guidance, signaling confidence in its diversified growth strategy.

Pure Resources advances its Reedy Creek project by exploring graphite potential and forging US partnerships to tap into thermal management and rare earth element technologies.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

City Chic Collective reports a promising FY25 with a return to profitability driven by strong ANZ sales and disciplined cost management, despite ongoing US market headwinds.

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.

Castile Resources has integrated bismuth as a by-product into its Rover 1 Bankable Feasibility Study following China’s export restrictions, positioning itself as a key supplier amid global supply shocks. The company also advances exploration with innovative technology and secures strategic partnerships in critical mineral supply chains.

Structural Monitoring Systems’ Canadian subsidiary has landed a $900,500 order from CAL FIRE for 50 advanced firefighting radios, marking a significant step in a broader fleet upgrade program.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.